Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model | Zendy

C. H. Chilton | Zendy; G. S. Crowther | Zendy; S. L. Todhunter | Zendy; Helen Ashwin | Zendy; Christopher Longshaw | Zendy; Alexei Karas | Zendy; Mark H. Wilcox | Zendy

Open Access

Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model

Author(s) -

C. H. Chilton,

G. S. Crowther,

S. L. Todhunter,

Helen Ashwin,

Christopher Longshaw,

Alexei Karas,

Mark H. Wilcox

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv156

Subject(s) - fidaxomicin , clostridium difficile , medicine , dosing , regimen , vancomycin , clindamycin , antibiotics , microbiology and biotechnology , gastroenterology , pharmacology , biology , bacteria , genetics , staphylococcus aureus

Fidaxomicin treatment reduces the risk of recurrent Clostridium difficile infection (CDI) compared with vancomycin. Extending duration of fidaxomicin therapy may further reduce recurrence. We compared the efficacy of four extended fidaxomicin regimens in an in vitro model of CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research